RIMI SANDHU: Open Payments
NPI 1770287203 · SPRING, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,986 in 160 payments from 21 companies in 2025. Trend: 2023 $106 · 2024 $2,210 · 2025 $2,986
Food & beverage: $2,976Education: $10
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $508 |
| ABBVIE INC. | 37 | $507 |
| E.R. Squibb & Sons, L.L.C. | 10 | $267 |
| Axsome Therapeutics, Inc. | 15 | $249 |
| Corium, LLC | 11 | $188 |
| Otsuka America Pharmaceutical, Inc. | 10 | $183 |
| Lundbeck LLC | 11 | $182 |
| Teva Pharmaceuticals USA, Inc. | 5 | $164 |
| Supernus Pharmaceuticals, Inc. | 9 | $162 |
| Neurocrine BioSciences, Inc. | 4 | $108 |
Products named: CAPLYTA, VRAYLAR, REXULTI, COBENFY, Auvelity, Azstarys, Qelbree, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
